x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0230259
| Product Information | |
|---|---|
| CAS No. | 1613695-14-9 |
| Chemical Name | 4-[(2S)-1-[2-[2-(3-chloro-4-methoxyphenyl)ethyl]-5-(3,5-dimethyl-1,2-oxazol-4-yl)benzimidazol-1-yl]propan-2-yl]morpholine |
| Formula | C28H33ClN4O3 |
| Molecular Weight | 509.00 |
| PubChem CID | 72201027 |
| SMILES | CC1=C(C(=NO1)C)C2=CC3=C(C=C2)N(C(=N3)CCC4=CC(=C(C=C4)OC)Cl)C[C@H](C)N5CCOCC5 |
| Target | p53 |
| Product Description | CREBBP/EP300 bromodomain inhibitor |
| Format & Storage | |
|---|---|
| Purity | > 98% |
| Source | Synthetic |
| Shipping | Shipped on dry ice. |
| Storage | Store at -20 °C. It is important to note that this is air sensitive and impurities can occur as a result of air oxidation. Store In the Dark. |
| Solubility Overview | DMSO (>30 mg/mL) |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
